IP Library Granted Patent US 9,642,998
Granted Patent B2
US 9,642,998 · App. 14/641,089 · Granted May 9, 2017

Pump systems and methods for storing and dispensing a plurality of precisely measured unit-doses of imiquimod cream

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,642,998
App. No.
14/641,089
Granted
May 9, 2017
Kind
B2
Abstract

The present invention is directed to airless storage and dispensing systems that include a pump or dispensing package pre-filled with a topical semi-solid imiquimod pharmaceutical formulation (“pump systems”) and methods for storing and dispensing from the pump systems a plurality of precisely measured and uniform unit doses of a topical semi-solid imiquimod pharmaceutical formulation, and more particularly to pump systems, pre-filled with a topical imiquimod pharmaceutical cream and methods for delivering multiple precisely measured unit doses of a topical imiquimod pharmaceutical cream, and methods for using a controlled delivery pump system to store and dispense a plurality of consistent and precisely measured unit doses of a topical imiquimod pharmaceutical cream for use in topically treating a dermal and mucosal-associated condition, such as, external genital warts and/or perianal warts (EGWs), actinic keratosis or actinic keratoses (AK or AKs) and superficial basal cell carcinoma (sBCC).

Claims (37)

1. A system for treating a subject diagnosed with a dermal and/or mucosal-associated condition, said system comprising:

a dispensing device that includes:

a lower subassembly that has a tubular body portion that defines an elongated interior fluid storage chamber into which a take-up piston element is slidably disposed; and

an upper subassembly mounted upon the lower subassembly and including a dispensing head and an airless pumping mechanism, the dispensing head having an internal fluid passage formed therein which terminates in a self-closing outlet, the dispensing head also including and a finger-operated actuator which is operatively associated with the airless pumping mechanism; and

an imiquimod cream formulation disposed at least partially within the fluid storage chamber defined in the tubular body portion of the lower subassembly of the dispensing package, and wherein operation of the finger-operated actuator causes the airless pumping mechanism to withdraw a portion of the imiquimod cream formulation from within the interior chamber and to dispense the imiquimod cream formulation into the internal fluid passage formed in the dispensing head wherein the pressure of dispensed cream causes the self-closing outlet to open thereby discharging a predefined effective unit dose amount of imiquimod cream from the dispensing package.

2. The system of claim 1 , wherein the imiquimod cream formulation contains imiquimod in an amount by weight of between 1% and 10% w/w.

3. The system of claim 1 , wherein the imiquimod cream formulation contains imiquimod in an amount by weight of between 1% and 5% w/w.

4. The system of claim 1 , wherein the imiquimod cream formulation contains imiquimod in an amount by weight selected from a group consisting of 2.5%, 3.75% and 5% w/w.

5. The system of claim 1 , wherein the fluid storage chamber is adapted and configured for storing about 7.5 grams of imiquimod cream formulation.

6. The system of claim 1 , wherein the take-up piston is disposed within the tubular body portion so as to partially define the fluid storage chamber, wherein the take-up position moves axially towards the pumping device when the pumping device is manually operated, so as to reduce the volume of the fluid storage chamber by an amount which is equivalent to the volume of imiquimod cream formulation dispensed from the dispensing package.

7. The system of claim 1 , wherein upon each operation of the pumping device an amount of the imiquimod cream formulation which is within about 15% of the predefined unit dose amount is discharged from the dispensing device.

8. The system of claim 1 , wherein after multiple operations of the pumping device, the overall average of the dose value is within about 10% of the predefined unit dose amount.

9. The system of claim 1 , wherein the predefined unit dose amount is about 240 mg.

10. The system of claim 1 , wherein no more than 5 manual actuations of the pumping mechanism are required in order to prime the pumping mechanism, and start observing the discharging of imiquimod cream formulation from the self-closing discharge orifice.

11. The system of claim 1 , wherein about 85% of the imiquimod cream formulation contained within the internal fluid passage of the dispensing head following an application remains in the internal fluid passage during storage.

12. The system of claim 1 , wherein the dermal and/or mucosal-associated condition comprises any of: external genital warts, perianal warts, actinic keratosis, and superficial basal cell carcinoma.

13. The system of claim 1 , wherein the dispensing package is configured so that a single actuation dispenses the predefined unit dose amount.

14. The system of claim 1 , further comprising:

a cap for sealing the self-closing outlet.

15. An airless pump pre-filled with an imiquimod cream for treating a subject diagnosed with a dermal and/or mucosal-associated condition with predefined single unit-dose amounts of the imiquimod cream dispensed from the pump, said airless pump comprising:

a dispensing device that includes:

a lower subassembly that has a tubular body portion that defines an elongated interior fluid storage chamber into which a take-up piston element is slidably disposed; and

an upper subassembly mounted upon the lower subassembly and including a dispensing head and an airless pumping mechanism, the dispensing head having an internal fluid passage formed therein which terminates in a self-closing outlet, the dispensing head also including and a finger-operated actuator which is operatively associated with the airless pumping mechanism; and

between about 5 grams and about 30 grams of the imiquimod cream disposed at least partially within the fluid storage chamber defined in the tubular body portion of the lower subassembly of the dispensing package,

wherein operation of the finger-operated actuator causes the airless pumping mechanism to withdraw a portion of the imiquimod cream from within the interior chamber and to dispense the imiquimod cream formulation into the internal fluid passage formed in the dispensing head,

wherein the pressure of the dispensed imiquimod cream causes the self-closing outlet to open thereby discharging the predefined single unit-dose amount of the imiquimod cream from the dispensing package,

wherein the take-up piston is disposed within the tubular body portion so as to partially define the fluid storage chamber, wherein the take-up position moves axially towards the pumping mechanism when the pumping mechanism is manually operated, so as to reduce the volume of the fluid storage chamber by an amount which is equivalent to the volume occupied by the predefined single effective unit-dose amount of the imiquimod cream dispensed from the dispensing package.

16. The airless pump of claim 15 , wherein the predefined single unit-dose amount is about 240 mg and the imiquimod cream comprises any of a 2.5% imiquimod cream, a 3.75% imiquimod cream, a 5% imiquimod cream.

17. The airless pump of claim 15 , wherein the pump is configured to dispense at least about 85% of the single unit dose amount during each said pumping step during treatment.

18. The airless pump of claim 15 , wherein the dispensing device is adapted to dispense a single product stored therein, the single product comprising the imiquimod formulation.

19. The airless pump of claim 15 , wherein the dispensing device is adapted to protect a remaining imiquimod formulation remaining within the dispensing device after each actuation from air contact, oxidation, degradation and contamination such that subsequent actuations of the dispensing device each dispense a subsequent effective unit-dose amount.

20. The airless pump of claim 15 , wherein the dispensing device is configured such that repeated actuations consistently and repeatedly dispense the effective unit-dose amount upon each actuation during treatment.

21. The airless pump of claim 15 , wherein the dispensing device is pre-filled with a pre-fill amount corresponding to the treatment regimen such that repeated actuations of the dispensing device deliver a predefined number of single unit-dose amounts effective to treat the dermal and/or mucosal condition in accordance with the effective treatment regimen.

22. The airless pump of claim 15 , wherein the dispensing device is configured such that a substantial portion of the imiquimod formulation drawn into the dispensing duct upon each actuation remains within the dispensing duct after actuation so that a uniform and consistent amount unit-dose of the imiquimod formulation is dispensed per each subsequent actuation.

23. The airless pump of claim 15 , wherein the dispensing device is configured such that about 85% or more of the imiquimod formulation drawn into the dispensing duct upon each actuation remains within the dispensing duct after actuation so that a uniform and consistent amount unit-dose of the imiquimod formulation is dispensed per each subsequent actuation.

24. The airless pump of claim 15 , wherein the dispensing device is configured such that an amount of the imiquimod formulation dispensed per one actuation is the same upon each subsequent actuation when actuating the dispensing device during treatment.

25. The airless pump of claim 15 , wherein the dispensing device is configured so as to not be readily disassemblable by the patient so that a remaining amount of imiquimod formulation remaining with the dispensing duct after each actuation remains effective and to avoid exposing the patient to excess imiquimod formulation.

Assignments (14)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
Reel/Frame 073637/0126 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
Reel/Frame 073654/0242 →
U.S. PATENT SECURITY AGREEMENT Recorded Jun 13, 2025
From: MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; BAUSCH HEALTH US, LLC (F/K/A VALEANT PHARMACEUTICALS NORTH AMERICA LLC); PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; BAUSCH HEALTH AMERICAS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 071564/0463 →
U.S. PATENT SECURITY AGREEMENT Recorded Jun 13, 2025
From: MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; BAUSCH HEALTH US, LLC (F/K/A VALEANT PHARMACEUTICALS NORTH AMERICA LLC); PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; BAUSCH HEALTH AMERICAS, INC.; SOLTA MEDICAL, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 071566/0200 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Oct 5, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061606/0468 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Oct 4, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061595/0066 →
SECURITY AGREEMENT Recorded Feb 10, 2022
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 059121/0001 →
SECURITY INTEREST Recorded Jun 8, 2021
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 056811/0814 →
SECURITY INTEREST Recorded Mar 11, 2019
From: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 048556/0758 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Jul 19, 2017
From: MEDICIS PHARMACEUTICAL CORPORATION
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043239/0675 →